Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Regulation of Nuclear Protein Sorting01:45

Regulation of Nuclear Protein Sorting

2.4K
Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
2.4K
Protein Complexes with Interchangeable Parts01:57

Protein Complexes with Interchangeable Parts

2.5K
Groups of proteins may form a complex where each protein in this complex has a different role in the overall execution of the complex’s function. Often some of the proteins in the complex can be replaced by a closely related variant to give a complex that contains many of the same components yet is functionally distinct.
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
2.5K
Protein Networks02:26

Protein Networks

3.9K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
3.9K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

11.4K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.4K
  1. Home
  3. Yap1 Status Defines Two Intrinsic Subtypes Of Lcnec With Distinct Molecular Features And Therapeutic Vulnerabilities
  1. Home
  3. Yap1 Status Defines Two Intrinsic Subtypes Of Lcnec With Distinct Molecular Features And Therapeutic Vulnerabilities

Related Experiment Video

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

6.9K

YAP1 Status Defines Two Intrinsic Subtypes of LCNEC with Distinct Molecular Features and Therapeutic Vulnerabilities

C Allison Stewart1, Lixia Diao2, Yuanxin Xi2

  • 1Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|August 16, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Large cell neuroendocrine carcinoma (LCNEC) has two subtypes based on YAP1 expression. YAP1-high LCNEC responds to MEK/AXL inhibitors, while YAP1-low LCNEC may benefit from SCLC-like therapies.

Frequently Asked Questions

More Related Videos

Validation of a Mouse Model to Disrupt LINC Complexes in a Cell-specific Manner
09:02

Validation of a Mouse Model to Disrupt LINC Complexes in a Cell-specific Manner

Published on: December 10, 2015

7.4K
All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System
09:55

All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System

Published on: December 20, 2021

2.9K

Related Experiment Videos

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

6.9K
Validation of a Mouse Model to Disrupt LINC Complexes in a Cell-specific Manner
09:02

Validation of a Mouse Model to Disrupt LINC Complexes in a Cell-specific Manner

Published on: December 10, 2015

7.4K
All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System
09:55

All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System

Published on: December 20, 2021

2.9K

Area of Science:

  • Molecular oncology and the clinical significance of YAP1 status.
  • The genomic characterization of Large Cell Neuroendocrine Carcinoma (LCNEC).
  • Translational research at the intersection of immunotherapy and transcriptomics.

Background:

Large cell neuroendocrine carcinoma (LCNEC) represents a high-grade pulmonary malignancy frequently characterized by aggressive progression and limited therapeutic options. Prior research has shown that this disease shares clinical similarities with small cell lung cancer (SCLC), including a lack of actionable oncogenic drivers and a generally dismal patient prognosis. Standard clinical management typically involves extrapolating treatment protocols from either small cell or non-small cell lung cancer frameworks due to a lack of disease-specific guidelines. While genomic profiling has identified common mutations in TP53 and RB1, the underlying biological heterogeneity of these tumors remains poorly understood. The absence of a robust molecular classification system prevents the development of precision medicine approaches tailored to the unique vulnerabilities of specific patient cohorts. Current diagnostic criteria often fail to capture the nuanced molecular differences that dictate how individual tumors respond to chemotherapy or immunotherapy. This absence of evidence motivated a comprehensive investigation into the intrinsic subtypes of this malignancy to identify biomarkers that could dictate more effective clinical interventions.

According to the study's authors, the presence of YAP1 leads to an inflamed, mesenchymal phenotype. In contrast, the absence of this protein results in an immune-cold, epithelial state. These distinct microenvironments are further characterized by specific co-occurring mutations in CDKN2A/B or RB1.

The researchers found that the YAP1-low subset is defined by the expression of transcription factors ASCL1 and NEUROD1. These markers are typically associated with small cell lung cancer. Their presence suggests that YAP1-low tumors share a common transcriptional lineage with other high-grade neuroendocrine malignancies.

The investigators utilized single-cell RNA sequencing to capture the high-resolution transcriptomic profiles of patient core needle biopsies. This method enabled the identification of ASCL1 and NEUROD1 as subtype-defining factors. It also allowed the team to distinguish between mesenchymal and epithelial cellular states within the tumor.

Based on this study's findings, the YAP1-low subset is molecularly confined to a profile that mirrors pure small cell lung cancer. This includes the presence of TP53 and RB1 co-mutations. Consequently, these tumors exhibit vulnerabilities to DLL3 and CD56 targeting, similar to SCLC paradigms.

The authors state that YAP1 status should be used to guide personalized treatment strategies for patients with this malignancy. The researchers conclude that identifying these intrinsic subtypes allows for the application of MEK, AXL, or DNA damage repair inhibitors based on the specific molecular features of the tumor.

Purpose Of The Study:

This investigation sought to define the biological landscape of large cell neuroendocrine carcinoma by identifying distinct molecular subsets through comprehensive genomic and transcriptomic analysis. Researchers focused on the expression of Yes-associated protein 1 (YAP1) as a potential master regulator of tumor phenotype and therapeutic response. The team intended to characterize the specific mutational profiles and immune microenvironments associated with different levels of this transcriptional coactivator. Identifying specific vulnerabilities in each subtype served as a primary objective to facilitate the development of targeted pharmacological and cellular therapies. The study also aimed to compare these subtypes with established small cell lung cancer models to determine if existing treatment paradigms are biologically justified. By utilizing high-resolution single-cell sequencing, the authors hoped to uncover the cellular diversity within core needle biopsies that traditional bulk sequencing might overlook. Establishing a clear link between transcriptional status and drug sensitivity was essential for proposing a new stratification framework for future clinical trials.

Main Methods:

The research team integrated genomic data from established cell lines and diverse patient cohorts to identify recurrent genetic alterations. Immunohistochemistry (IHC) provided spatial protein expression data to validate the presence of specific biomarkers across tissue samples. Single-cell Ribonucleic Acid (RNA) sequencing of core needle biopsies from patients and preclinical models allowed for high-resolution transcriptomic profiling of the tumor microenvironment. Computational analysis of these sequencing datasets enabled the clustering of tumors based on their transcriptional signatures and the identification of subtype-defining transcription factors. Preclinical testing involved the evaluation of pharmacological inhibitors targeting Mitogen-activated protein kinase (MEK) and AXL receptor tyrosine kinase. The investigators also developed and tested novel chimeric antigen receptor (CAR) T-cells engineered to target AXL, Delta-like ligand 3 (DLL3), and CD56 in various experimental settings. Statistical frameworks were applied to correlate the expression of Yes-associated protein 1 with specific mutational landscapes and therapeutic outcomes in both in vitro and in vivo models.

Main Results:

Analysis revealed that the presence or absence of Yes-associated protein 1 (YAP1) effectively partitions large cell neuroendocrine carcinoma into two distinct biological subsets. The YAP1-high group exhibited a mesenchymal phenotype and an inflamed immune microenvironment, frequently harboring co-occurring mutations in CDKN2A/B and SMARCA4 alongside TP53. Pharmacological screening showed that these YAP1-high tumors are particularly sensitive to MEK and AXL inhibition, as well as AXL-directed chimeric antigen receptor T-cell therapy. Conversely, the YAP1-low subset displayed epithelial characteristics and an immune-cold profile, with a high prevalence of TP53 and RB1 co-mutations. This YAP1-low group expressed transcription factors such as Achaete-scute homolog 1 (ASCL1) and Neuronal differentiation 1 (NEUROD1), mirroring the molecular landscape of small cell lung cancer. Therapeutic testing in the YAP1-low models demonstrated significant sensitivity to DNA damage repair inhibition and cellular therapies targeting DLL3 and CD56. These findings confirm that YAP1 status is a reliable indicator of both the underlying oncogenic drivers and the potential efficacy of subtype-specific treatments.

Conclusions:

The findings establish that YAP1 status serves as a primary molecular determinant of the identity of large cell neuroendocrine carcinoma. Distinct biological pathways drive the progression of these subtypes, suggesting that a one-size-fits-all treatment approach is likely suboptimal for this patient population. The identification of specific genetic co-alterations provides a roadmap for selecting patients who may benefit from targeted inhibitors or novel immunotherapies. These results support the clinical development of AXL, DLL3, and CD56-targeted chimeric antigen receptor T-cells as precision medicine tools. Future clinical trials should incorporate YAP1 expression as a stratification factor to improve the efficacy of therapeutic interventions. This research provides a necessary foundation for shifting the management of this malignancy toward a biomarker-driven paradigm similar to other lung cancers. Ultimately, the study suggests that molecular subtyping can transform the prognosis of patients by matching them with therapies that exploit their tumor's specific biological weaknesses.